AU StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

Resmed DRC

37.260

+0.3600.98%

Volume:534.78K

Turnover:19.89M

Market Cap:54.63B

PE:29.11

High:37.320

Open:36.850

Low:36.720

Close:36.900

Loading ...

Overview Company News Filings

How to build a winning $250,000 ASX share portfolio starting from zero

3 of the best ASX 200 healthcare shares to bring your portfolio to life

5 top ASX 200 stocks that brokers rate as buys after the market selloff

CSL, Resmed Are Morgan Stanley's Australia Healthcare Picks in the Tariff Era -- Market Talk

Morgan Stanley’s top-ranked ASX healthcare picks for right now

How I'd invest in ASX 200 shares if I wanted to sleep well during market volatility

ResMed Bull Braces for Possible Short-Lived Selloff -- Market Talk

What I'd buy if I wanted to turn $10,000 into $100,000 with ASX shares

3 ASX 200 stocks I'd buy and hold for the next 10 years

“We’re buying”: Emma Fisher spots a rare chance to upgrade the portfolio

ResMed Inc. Stock Falls Thursday, Still Outperforms Market

Why I'm taking a closer look at ResMed shares

The Fallen: Stocks hitting 52-week lows (and what investors should do)

5 undervalued ASX stocks that could rise as AUD weakens

Trump 2.0: Macquarie's take on the winners and losers in Australian healthcare

ResMed's Fiscal Q3 Likely to Meet Consensus Estimates; Faces Supply Chain Risks, UBS Says

MT Newswires Live

ResMed CFO Sells Shares

MT Newswires Live

ResMed Inc. Stock Falls Tuesday, Underperforms Market

Strength Seen in ResMed (RMD): Can Its 3.8% Jump Turn into More Strength?

Q4 Patient Monitoring Earnings Review: First Prize Goes to Masimo (NASDAQ:MASI)

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/RMD.AU/news?page=3"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"RMD.AU","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"RMD.AU\",,,,,undefined,":{"symbol":"RMD.AU","market":"AU","secType":"STK","nameCN":"Resmed DRC","latestPrice":37.26,"timestamp":1746166320000,"preClose":36.9,"halted":0,"volume":534783,"delay":0,"nameEN":"Resmed DRC","floatShares":145691036,"shares":1466188140,"eps":1.2803958207880408,"marketStatus":"Market Closed","change":0.36,"latestTime":"05-02 16:12:00 AEST","open":36.85,"high":37.32,"low":36.72,"amount":19886061,"amplitude":0.01626,"askPrice":37.29,"askSize":26,"bidPrice":37.07,"bidSize":580,"shortable":3,"etf":0,"ttmEps":1.2803958207880408,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":0,"beginTime":1746403200000},"marketStatusCode":7,"adr":0,"adrRate":1,"exchange":"ASX","adjPreClose":36.9,"dividendRate":0.008293,"openAndCloseTimeList":[[1746144000000,1746165600000]],"volumeRatio":0.258836,"lotSize":1,"tradeCurrency":"AUD"},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"RMD.AU\",,,,,undefined,":{"symbol":"RMD.AU","floatShares":145691036,"roa":"14.01%","roe":"25.81%","lyrEps":0.969825,"volumeRatio":0.258836,"shares":1466188140,"dividePrice":0.305689,"high":37.32,"amplitude":0.01626,"preClose":36.9,"low":36.72,"week52Low":26.946,"pbRate":"6.35","psRate":"7.01","week52High":40.661,"institutionHeld":0,"latestPrice":37.26,"committee":0.914191,"eps":1.2801693237292187,"divideRate":0.008293,"volume":534783,"delay":0,"ttmEps":1.2801693237292187,"open":36.85,"prevYearClose":36.689,"prevWeekClose":36.08,"prevMonthClose":36.68,"prevQuarterClose":34.96,"fiveDayClose":36.08,"twentyDayClose":35.63,"sixtyDayClose":38.874},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"RMD.AU\",pageSize:20,pageCount:3,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2527765204","title":"How to build a winning $250,000 ASX share portfolio starting from zero","url":"https://stock-news.laohu8.com/highlight/detail?id=2527765204","media":"MotleyFool","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2527765204?lang=en_us&edition=fundamental","pubTime":"2025-04-16 05:07","pubTimestamp":1744751220,"startTime":"0","endTime":"0","summary":"Building a $250,000 ASX share portfolio from scratch might seem like a big challenge, but with patience, discipline, and the right strategy, it is entirely possible. The key is to start investing earl","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.fool.com.au/2025/04/16/how-to-build-a-winning-250000-asx-share-portfolio-starting-from-zero/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"motleyfoolau_stock","symbols":["GMG.AU","BK7099","BK7016","RMD.AU","BK7155","BK7503","NDQ.AU","BK7510","VAS.AU","BK7007","BK7501","TNE.AU"],"gpt_icon":0},{"id":"2527447668","title":"3 of the best ASX 200 healthcare shares to bring your portfolio to life","url":"https://stock-news.laohu8.com/highlight/detail?id=2527447668","media":"MotleyFool","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2527447668?lang=en_us&edition=fundamental","pubTime":"2025-04-16 02:00","pubTimestamp":1744740000,"startTime":"0","endTime":"0","summary":"If your portfolio needs a health check, then the healthcare sector could be just what the doctor ordered. ASX 200 healthcare shares have a history of delivering strong, long-term returns thanks to con","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.fool.com.au/2025/04/16/3-of-the-best-asx-200-healthcare-shares-to-bring-your-portfolio-to-life/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"motleyfoolau_stock","symbols":["LU0061475181.USD","LU2237443549.SGD","IE00B19Z3581.USD","LU0048573561.USD","PME.AU","BK4585","BK7511","LU1868837136.USD","BK7007","BK4550","IE00B19Z3B42.SGD","LU0251142724.SGD","LU0106831901.USD","LU1868836914.USD","IE0004091025.USD","IE00BSNM7G36.USD","LU2471134796.USD","LU2237443465.HKD","BK4504","LU1868837300.USD","LU2471134952.CNY","LU2471134523.USD","IE00BFXG1179.USD","LU2237438978.USD","LU2471134879.HKD","BK7067","BK7508","LU1868836757.USD","LU2237443895.HKD","BK4552","BK4127","LU0742534661.SGD","LU2237443978.SGD","IE0004086264.USD","IE0002270589.USD","IE0034235188.USD","BK7501","LU2750360997.AUD","LU1868836591.USD","LU2237443622.USD","CSL.AU","BK4516","LU2237443382.USD","LU1668664300.SGD","BK7094","BK4533","RMD.AU","BK4588","LU2750360641.GBP","LU1791807156.HKD"],"gpt_icon":0},{"id":"2527448763","title":"5 top ASX 200 stocks that brokers rate as buys after the market selloff","url":"https://stock-news.laohu8.com/highlight/detail?id=2527448763","media":"MotleyFool","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2527448763?lang=en_us&edition=fundamental","pubTime":"2025-04-15 15:10","pubTimestamp":1744701034,"startTime":"0","endTime":"0","summary":"If you are on the lookout for some investment ideas, then it could be worth checking out what analysts saying. Listed below are five ASX 200 stocks that leading brokers currently rate as buy. Here's w","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.fool.com.au/2025/04/15/5-top-asx-200-stocks-that-brokers-rate-as-buys-after-the-market-selloff/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"motleyfoolau_stock","symbols":["WTC.AU","BK7044","JHX.AU","RMD.AU","BK7511","XRO.AU","BK7501","BK7503","BK7067","TLX.AU","BK7046","BK7016","MQG.AU","BK7007"],"gpt_icon":1},{"id":"2527481820","title":"CSL, Resmed Are Morgan Stanley's Australia Healthcare Picks in the Tariff Era -- Market Talk","url":"https://stock-news.laohu8.com/highlight/detail?id=2527481820","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2527481820?lang=en_us&edition=fundamental","pubTime":"2025-04-15 11:51","pubTimestamp":1744689060,"startTime":"0","endTime":"0","summary":"0351 GMT - Biopharmaceutical company CSL and medical equipment firm Resmed have the best combination of attractive valuation and low tariff impact among Australian healthcare stocks, suggests Morgan Stanley equity analyst David L. Bailey. He estimates that CSL would need to raise prices by 1% and Resmed would need to raise prices by 2%-3% to offset the earnings impact from tariffs. But given their solid earnings per share growth, low earnings risk and valuation appeal, he says these companies are the \"most favorably positioned\" among peers. One word of caution--pharmaceuticals are currently excluded from reciprocal tariffs, but Trump has signaled he wants to put tariffs on that sector soon, which could impact CSL. ","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RMD.AU","LU0158827781.USD","LU0158827948.USD","SGXZ23171101.USD","LU0795875169.SGD","BK7511","LU0795875086.SGD","BK4127","LU0971096721.USD","BK4516","LU1162221912.USD","LU1732800096.USD","LU0912757837.SGD","LU1169590202.USD","RMD","BK4534","LU1074936037.SGD","MS","BK7508","LU0728928796.USD","LU2177674079.SGD","SG9999004303.SGD","LU1720051017.SGD","LU1668664300.SGD","LU1363072403.SGD","BK4082","LU0170899867.USD","CSL","LU0106831901.USD","LU2271345857.HKD","LU1989772840.SGD","BK4567","BK4588","BK4548","BK4086","BK4581","LU2089284900.SGD","HCSG","LU2089283258.USD","CSL.AU","LU2023251221.USD","LU0225283273.USD","LU0098860793.USD","LU1720051108.HKD","LU0314104364.USD","LU2347655156.SGD","LU0320765646.SGD","BK7501","LU1548497426.USD","BK4137"],"gpt_icon":1},{"id":"2527107074","title":"Morgan Stanley’s top-ranked ASX healthcare picks for right now","url":"https://stock-news.laohu8.com/highlight/detail?id=2527107074","media":"LiveWire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2527107074?lang=en_us&edition=fundamental","pubTime":"2025-04-15 10:46","pubTimestamp":1744685174,"startTime":"0","endTime":"0","summary":"Despite the latest noises out of the White House promising some tariff respite, Trump’s ongoing trade war remains the big spectre looming over markets.According to research from Morgan Stanley, one sector that could weather the storm is healthcare, especially if the worst were to happen and we entered a period of stagflation or even recession.Here are its two big-name stock picks and the reasons it thinks the sector is well-positioned right now.While pharmaceuticals are currently exempt from US tariffs, Trump hinted that an announcement on specific pharma tariffs could be expected “soon”.Regardless, Morgan Stanley believes leading ASX health stocks should be able to offset any tariff impact through minimal price increases.Using the GFC as an instructive case study, Morgan Stanley reviewed the performance of the healthcare industry against the ASX 200during that time in case we entered a similar period of lower growth, higher inflation and more unemployment.According to Morgan Stanley's","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"livewire_stock","url":"https://www.livewiremarkets.com/wires/morgan-stanley-s-top-ranked-asx-healthcare-picks-for-right-now","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.livewiremarkets.com/wires/morgan-stanley-s-top-ranked-asx-healthcare-picks-for-right-now","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"livewire_stock","symbols":["LU2271345857.HKD","LU0912757837.SGD","LU0158827948.USD","BK4585","BK4127","BK7067","LU1363072403.SGD","LU1732800096.USD","LU2357305700.SGD","LU0971096721.USD","LU2133065610.SGD","CSL.AU","LU2089283258.USD","LU0006306889.USD","BK4516","LU0267386448.USD","LU1720051108.HKD","LU2023251221.USD","BK4504","LU0314104364.USD","BK7007","LU2089284900.SGD","LU0106261372.USD","IE00BKVL7J92.USD","BK7501","LU0795875086.SGD","LU1162221912.USD","LU1732799900.SGD","MS","IE00BZ1G4Q59.USD","LU1720051017.SGD","LU1548497426.USD","RMD.AU","LU0158827781.USD","LU2347655156.SGD","LU0106831901.USD","BK4588","LU1074936037.SGD","BK4581","LU0320765646.SGD","LU1989772840.SGD","LU1989772923.USD","BK7511","LU0225283273.USD","LU2028103732.USD","LU1668664300.SGD","LU0098860793.USD","LU2111349929.HKD","LU0795875169.SGD","BK7508"],"gpt_icon":0},{"id":"2527713444","title":"How I'd invest in ASX 200 shares if I wanted to sleep well during market volatility","url":"https://stock-news.laohu8.com/highlight/detail?id=2527713444","media":"MotleyFool","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2527713444?lang=en_us&edition=fundamental","pubTime":"2025-04-14 17:33","pubTimestamp":1744623232,"startTime":"0","endTime":"0","summary":"Let's face it — the share market can be a stressful place when prices are falling, headlines are screaming, and your portfolio is flashing red. But the truth is, volatility is part of the investment r","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.fool.com.au/2025/04/14/how-id-invest-in-asx-200-shares-if-i-wanted-to-sleep-well-during-market-volatility/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"motleyfoolau_stock","symbols":["BK7501","BK4585","RMD.AU","QLTY.AU","IVV.AU","BK7510","BK7508","BK4588","BK7511","FDN","BK7067","CSL.AU","BK4550","GMG.AU","COL.AU","BK7007","BK7042","NDQ.AU","TLS.AU","BK7155","BK7082","BK7040","BK7099"],"gpt_icon":0},{"id":"2527382915","title":"ResMed Bull Braces for Possible Short-Lived Selloff -- Market Talk","url":"https://stock-news.laohu8.com/highlight/detail?id=2527382915","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2527382915?lang=en_us&edition=fundamental","pubTime":"2025-04-14 07:21","pubTimestamp":1744586460,"startTime":"0","endTime":"0","summary":"2321 GMT -- ResMed's bull at Citi is bracing for the possibility of a short-lived share sell-off when trial results from Eli Lilly's Orforglipron weight-loss drug are announced. Analyst Mathieu Chevrier keeps a buy rating on the breathing-tech provider, but opens a 90-day downside catalyst watch on the release of Orforglipron's phase 3 readout, which is expected some time in the June quarter. Chevrier reminds clients in a note that ResMed's share price has reacted negatively to GLP-1 news in the past, but he doesn't expect any selloff to be long-lasting. Citi has a A$44.00 target price on the stock, which is at A$34.21 ahead of the open. ","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2008162690.USD","BK4585","RMD.AU","BK4082","BK4504","RMD","LU0170899867.USD","BK7501","LU2177674079.SGD","BK4567","BK7007","BK4548","BK4588"],"gpt_icon":1},{"id":"2527329935","title":"What I'd buy if I wanted to turn $10,000 into $100,000 with ASX shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2527329935","media":"MotleyFool","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2527329935?lang=en_us&edition=fundamental","pubTime":"2025-04-13 06:06","pubTimestamp":1744495560,"startTime":"0","endTime":"0","summary":"You'll probably be waiting a long time. The better approach is to start with what you have, invest in quality, and stay consistent. This is where dollar cost averaging can help — buying regularly smooths out volatility and removes the guesswork. The real secret isn't predicting the next breakout winner — it is being early, being patient, and staying disciplined. What would I buy?Personally, I'd be looking for long-term compounders with real staying power. Businesses like ResMed Inc , WiseTech Global Ltd , and Xero Ltd , or an ETF like BetaShares Nasdaq 100 ETF  or VanEck Morningstar Wide Moat ETF  — names that don't just grow, but compound earnings over time. They won't all shoot the lights out overnight. But give them a decade or more, and they could do some serious heavy lifting. Foolish takeaway Growing $10,000 into $100,000 isn't about luck. It is about owning great businesses, staying invested, and letting time do what time does best. It might take years. It will definitely","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.fool.com.au/2025/04/13/what-id-buy-if-i-wanted-to-turn-10000-into-100000-with-asx-shares/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"motleyfoolau_stock","symbols":["XRO.AU","BK4585","WTC.AU","RMD.AU","BK4550","BK7503","MOAT.AU","BK7501","BK7016","NDQ.AU","BK7007","FDN","BK4588"],"gpt_icon":0},{"id":"2526629371","title":"3 ASX 200 stocks I'd buy and hold for the next 10 years","url":"https://stock-news.laohu8.com/highlight/detail?id=2526629371","media":"MotleyFool","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2526629371?lang=en_us&edition=fundamental","pubTime":"2025-04-12 07:04","pubTimestamp":1744412640,"startTime":"0","endTime":"0","summary":"There's something powerful about backing a great business and simply holding on. Not for six months. Not until the next earnings update. But for a full decade — riding the waves, ignoring the noise, a","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.fool.com.au/2025/04/12/3-asx-200-stocks-id-buy-and-hold-for-the-next-10-years/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"motleyfoolau_stock","symbols":["BK4533","BK4585","IE0002270589.USD","LU0048573561.USD","IE00BSNM7G36.USD","IE0034235188.USD","LU0106831901.USD","LU0742534661.SGD","BK7016","BK4588","LU2237443978.SGD","IE00B19Z3581.USD","LU0096364046.USD","IE0004086264.USD","LU2750360997.AUD","LIF","LU0251142724.SGD","LU2471134523.USD","BK4552","BK4504","BK7503","LU1868836591.USD","360.AU","LU0251131958.USD","LU2750360641.GBP","LU2237438978.USD","LU1868836914.USD","BK7007","IE00BFXG1179.USD","LU1868836757.USD","LU1868837136.USD","LU1668664300.SGD","LU2237443895.HKD","LU2471134952.CNY","BK4023","BK4613","LU2237443465.HKD","BK4550","LU1791807156.HKD","IE0004091025.USD","BK4127","LU2471134879.HKD","WTC.AU","LU1868837300.USD","IE00B19Z3B42.SGD","LU0061475181.USD","RMD.AU","LU2237443622.USD","BK7501","LU2237443549.SGD"],"gpt_icon":0},{"id":"2526050775","title":"“We’re buying”: Emma Fisher spots a rare chance to upgrade the portfolio","url":"https://stock-news.laohu8.com/highlight/detail?id=2526050775","media":"LiveWire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2526050775?lang=en_us&edition=fundamental","pubTime":"2025-04-11 13:30","pubTimestamp":1744349406,"startTime":"0","endTime":"0","summary":"Note: This podcast was recorded on the 9th of April 2025. Monday the 7th of April 2025 is a day few Aussie investors will forget, as the ASX 200 opened more than 6% lower on fears of escalating trade wars. The drop followed a sharp fall on US markets, capping what was the worst two-day period since March 2020.The moves took US stocks into bear market territory, leaving investors asking the question: “How low can this go?”For Emma Fisher, Deputy Head of Equities at Airlie Funds Management, it was a phone call from her mum that delivered a ‘soft signal’ that the worst of the selling may be behind us.Fisher, a self-confessed optimist, has been making the case for some time that equities were expensive and susceptible to a drawdown. Earnings and dividends on the ASX have been flat for the past two years, with equity returns driven largely by multiple expansion - often used as a proxy for investor exuberance.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"livewire_stock","url":"https://www.livewiremarkets.com/wires/we-re-buying-emma-fisher-spots-a-rare-chance-to-upgrade-the-portfolio","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.livewiremarkets.com/wires/we-re-buying-emma-fisher-spots-a-rare-chance-to-upgrade-the-portfolio","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"livewire_stock","symbols":["SIG.AU","RMD.AU","XAO.AU","XKO.AU","BK7007","BK7103","XJO.AU","BK7078","AASF.AU","BK7001","BK7501","JBH.AU","ALL.AU"],"gpt_icon":0},{"id":"2526544083","title":"ResMed Inc. Stock Falls Thursday, Still Outperforms Market","url":"https://stock-news.laohu8.com/highlight/detail?id=2526544083","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2526544083?lang=en_us&edition=fundamental","pubTime":"2025-04-11 04:56","pubTimestamp":1744318560,"startTime":"0","endTime":"0","summary":"This article was automatically generated by MarketWatch using technology from Automated Insights.Shares of ResMed Inc.  slipped 2.72% to $210.55 Thursday, on what proved to be an all-around grim trading session for the stock market, with the S&P 500 Index  falling 3.46% to 5,268.05 and Dow Jones Industrial Average  falling 2.50% to 39,593.66.ResMed Inc. closed 19.96% below its 52-week high of $263.05, which the company achieved on January 30th.Trading volume  remained 33,424 below its 50-day average volume of 1.1 M.Data source: Dow Jones Market Data, FactSet. Data compiled April 10, 2025.This content was created by MarketWatch, which is operated by Dow Jones & Co. MarketWatch is published independently from Dow Jones Newswires and The Wall Street Journal.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RMD","RMD.AU"],"gpt_icon":0},{"id":"2526304027","title":"Why I'm taking a closer look at ResMed shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2526304027","media":"MotleyFool","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2526304027?lang=en_us&edition=fundamental","pubTime":"2025-04-10 12:21","pubTimestamp":1744258896,"startTime":"0","endTime":"0","summary":"By most accounts, ResMed shares look to be squarely in the buy zone. According to broker Macquarie, ResMed is sufficiently positioned to withstand the brunt of President Trump's tariff fallout.  The broker notes that Resmed will be cushioned from the tariff blows because a significant portion of the company's manufacturing is conducted in the United States. Goldman Sachs also sees potential in the ResMed share price at its current valuation. The broker has a price target of $49 on ResMed shares. That represents a potential upside of 40%. As such, ResMed sits high up on my watch list.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.fool.com.au/2025/04/10/why-im-taking-a-closer-look-at-resmed-shares/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"motleyfoolau_stock","symbols":["BK4504","LU2177674079.SGD","RMD","LU0170899867.USD","BK4082","BK7007","LU2008162690.USD","BK4585","RMD.AU","BK4548","BK4567","BK7501","BK4588"],"gpt_icon":1},{"id":"2526364374","title":"The Fallen: Stocks hitting 52-week lows (and what investors should do)","url":"https://stock-news.laohu8.com/highlight/detail?id=2526364374","media":"LiveWire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2526364374?lang=en_us&edition=fundamental","pubTime":"2025-04-10 10:48","pubTimestamp":1744253281,"startTime":"0","endTime":"0","summary":"Earlier this week, I covered The Outlaws – stocks hitting 52-week highs despite the market sinking.The Outlaw Stocks: The ASX names defying the sell-off and hitting 52-week highs. Unlike in 2022, when almost every asset class fell in lockstep, this year we’ve seen defensives and fixed income ETFs do what they’re meant to do: offer ballast in a storm.Now, let's flip the script and look at the stocks and ETFs which hit 52-week lows before today's bigger-than-Ben-Hur rally. We'll call them:The Fallen.To be sure, these aren’t necessarily all bad businesses. As fund managers like Emanuel Datt, Adam Dawes, and Nick Peros have pointed out, a stock hitting a 52-week low isn’t always a red flag.It's a potential opportunity to pick up quality at a discount.Due to the sheer number of names hitting 52-week low, we’ve  focused this wire on two key ASX sectors – resources and financials – with expert insights to help investors make sense of the wreckage.You can download the full list below or use th","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"livewire_stock","url":"https://www.livewiremarkets.com/wires/the-fallen-stocks-hitting-52-week-lows-and-what-investors-should-do","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.livewiremarkets.com/wires/the-fallen-stocks-hitting-52-week-lows-and-what-investors-should-do","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"livewire_stock","symbols":["BK7508","LU2028103732.USD","MQG.AU","LU0912757837.SGD","LU0225283273.USD","CSL.AU","RIO.AU","LU0158827948.USD","RMD","BHP.AU","BK4127","BK4552","BK7002","LU0742534661.SGD","LU1732800096.USD","LU2089283258.USD","BK7507","LU1162221912.USD","LU2023251221.USD","LU1868837136.USD","LU0795875086.SGD","LU0170899867.USD","LU1548497426.USD","RMD.AU","BK4585","MIN.AU","XRO.AU","BK4550","LU2471134796.USD","NDQ.AU","MFG.AU","LU2237443549.SGD","GQG.AU","IE00B19Z3B42.SGD","REA.AU","TNE.AU","LU2089284900.SGD","LU0251131958.USD","BK7016","PNI.AU","LU0314104364.USD","LU2471134523.USD","NXL","LU2237438978.USD","LU2237443978.SGD","LU2471134879.HKD","LU0795875169.SGD","NXL.AU","LU2008162690.USD","BK4516"],"gpt_icon":0},{"id":"2526347223","title":"5 undervalued ASX stocks that could rise as AUD weakens","url":"https://stock-news.laohu8.com/highlight/detail?id=2526347223","media":"LiveWire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2526347223?lang=en_us&edition=fundamental","pubTime":"2025-04-10 06:54","pubTimestamp":1744239297,"startTime":"0","endTime":"0","summary":"As stock markets at home and abroad continue to whiplash in the washing machine of Trump’s tariff war, one thing remains depressingly predictable.The Australian dollar continues its long decline, with the case for additional RBA rate cuts and the impact of tariffs on Chinese industry pushing the Pacific Peso lower against all major currencies.This week, the Aussie dollar dropped to a five-year low against the US dollar, at 0.59 USD, and is on the verge of dropping to a 23-year low if the downtrend continues.So where should Australian investors turn when both the ASX and AUD are struggling?One idea would be to look for ASX companies that earn the majority of their money in the US.As UBS strategist Richard Schellbach wrote in a recent strategy piece, “candidates for de-rate opportunities are likely to be found in the list of Australian stocks that source earnings from America.”Of these, we then applied the following filters to produce a list of five stocks that could be under-valued and ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"livewire_stock","url":"https://www.livewiremarkets.com/wires/5-undervalued-asx-stocks-that-could-rise-as-aud-weakens","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.livewiremarkets.com/wires/5-undervalued-asx-stocks-that-could-rise-as-aud-weakens","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"livewire_stock","symbols":["BK7012","LNW.AU","GQG.AU","XAO.AU","BK7007","BK7062","BK7053","BK7078","BK7501","ORA.AU","RWC.AU","XKO.AU","RMD.AU","XJO.AU"],"gpt_icon":0},{"id":"2526990342","title":"Trump 2.0: Macquarie's take on the winners and losers in Australian healthcare","url":"https://stock-news.laohu8.com/highlight/detail?id=2526990342","media":"MotleyFool","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2526990342?lang=en_us&edition=fundamental","pubTime":"2025-04-10 05:12","pubTimestamp":1744233120,"startTime":"0","endTime":"0","summary":"] A key challenge for both RMD and FPH will be negotiations with US payors to increase pricing or widening co-payments. We note upside risk for both names if respiratory devices/apparatus are exempt from tariffs under the Nairobi Protocol implemented through the Harmonised Tariff Schedule.  That said, ResMed isn't completely immune. With part of its manufacturing based in Australia and Singapore, both now facing 10% tariffs, and rising input costs from tariffed raw materials, its earnings forecasts have been trimmed by 2% for FY 2026 and FY 2027. What about CSL and Cochlear?Biotech giant CSL Ltd  escaped the current round of tariffs, thanks to exemptions for pharmaceutical products. However, Macquarie flagged it as a name to watch. It said:  CSL is left unscathed by reciprocal tariffs as pharmaceuticals are exempted. However, potential sector tariffs remain a key risk for CSL in the near term.  As for Cochlear Ltd , it also sidestepped the tariff net, as hearing devices continue to enj","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.fool.com.au/2025/04/10/trump-2-0-macquaries-take-on-the-winners-and-losers-in-australian-healthcare/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"motleyfoolau_stock","symbols":["MQG.AU","XKO.AU","XAO.AU","BK7508","FPH.AU","XJO.AU","BK7126","BK7511","RMD.AU","ANN.AU","CSL.AU","COH.AU","BK7046","BK7007","BK7501","BK7067"],"gpt_icon":0},{"id":"2526312885","title":"ResMed's Fiscal Q3 Likely to Meet Consensus Estimates; Faces Supply Chain Risks, UBS Says","url":"https://stock-news.laohu8.com/highlight/detail?id=2526312885","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2526312885?lang=en_us&edition=fundamental","pubTime":"2025-04-10 02:45","pubTimestamp":1744224348,"startTime":"0","endTime":"0","summary":"ResMed's  fiscal Q3 is likely to meet consensus estimates, but the company is facing potential supply chain disruption risks due to US tariffs, UBS said in a Wednesday note.UBS estimates fiscal Q3 revenue of $1.28 billion and a core gross margin of roughly 60%, both in line with Visible Alpha consensus. It also estimates core earnings of $2.32 per share, which is slightly below the consensus, according to the note.The brokerage said it forecasts a roughly 1% negative near-term impact on EPS due to tariffs and is \"mindful\" of freight costs and their potential impact on the company's gross margins.ResMed will report its fiscal Q3 financial results on April 23.UBS said ResMed is working to lift gross margins above 60%, and it sees \"core gross margin back at that level in FY25, which is more optimistic than the consensus expectation of FY26.\"UBS maintained its buy rating on the stock and 12-month price target of $290 per share.Price: 214.92, Change: +10.38, Percent Change: +5.07","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LU0170899867.USD","RMD.AU","BK4082","BK7501","LU2177674079.SGD","RMD","BK4588","BK4548","BK4585","LU2008162690.USD","BK7007","BK4567","BK4504"],"gpt_icon":0},{"id":"2526182795","title":"ResMed CFO Sells Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2526182795","media":"MT Newswires Live","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2526182795?lang=en_us&edition=fundamental","pubTime":"2025-04-09 07:48","pubTimestamp":1744156090,"startTime":"0","endTime":"0","summary":"ResMed's  Chief Financial Officer Brett Sandercock sold 1,000 common shares on the New York Stock Exchange for $215,580 in total, according to a Wednesday filing with the Australian bourse.Following the sale of shares, Sandercock owns about 146.9 million shares in the company, per the filing.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4504","LU2177674079.SGD","RMD","LU0170899867.USD","BK4082","BK7007","XAO.AU","LU2008162690.USD","BK4585","XKO.AU","XJO.AU","RMD.AU","BK4548","BK4567","BK7501","BK4588"],"gpt_icon":0},{"id":"2526082325","title":"ResMed Inc. Stock Falls Tuesday, Underperforms Market","url":"https://stock-news.laohu8.com/highlight/detail?id=2526082325","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2526082325?lang=en_us&edition=fundamental","pubTime":"2025-04-09 04:56","pubTimestamp":1744145760,"startTime":"0","endTime":"0","summary":"This article was automatically generated by MarketWatch using technology from Automated Insights.Shares of ResMed Inc.  slipped 3.97% to $204.54 Tuesday, on what proved to be an all-around poor trading session for the stock market, with the S&P 500 Index  falling 1.57% to 4,982.77 and Dow Jones Industrial Average  falling 0.84% to 37,645.59.ResMed Inc. closed 22.24% short of its 52-week high of $263.05, which the company achieved on January 30th.Trading volume  eclipsed its 50-day average volume of 1.1 M.Data source: Dow Jones Market Data, FactSet. Data compiled April 8, 2025.This content was created by MarketWatch, which is operated by Dow Jones & Co. MarketWatch is published independently from Dow Jones Newswires and The Wall Street Journal.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RMD","RMD.AU"],"gpt_icon":0},{"id":"2525781677","title":"Strength Seen in ResMed (RMD): Can Its 3.8% Jump Turn into More Strength?","url":"https://stock-news.laohu8.com/highlight/detail?id=2525781677","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2525781677?lang=en_us&edition=fundamental","pubTime":"2025-04-08 20:39","pubTimestamp":1744115940,"startTime":"0","endTime":"0","summary":"ResMed RMD shares rallied 3.8% in the last trading session to close at $213. This move can be attributable to notable volume with a higher number of shares being traded than in a typical session. This compares to the stock's 11.7% loss over the past four weeks.ResMed scored a strong price increase, on investors’ optimism surrounding its impending fiscal 2025 third-quarter financial results, which is slated to release on April 23 after market close. In the last reported quarter, the company achieved robust revenue growth across all product and geographic categories. Additionally, market is also upbeat about the company’s latest launch of NightOwl - an FDA-cleared home sleep apnea test , across the United States.This maker of medical products for respiratory disorders is expected to post quarterly earnings of $2.36 per share in its upcoming report, which represents a year-over-year change of +10.8%. Revenues are expected to be $1.28 billion, up 7.3% from the year-ago quarter.Earnings and","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/strength-seen-resmed-rmd-3-123900551.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU2008162690.USD","BK4175","BK4504","BK4548","LU2177674079.SGD","RMD.AU","BK4567","LU0170899867.USD","RMD","BK4585","BK4082","BK4588","AHCO"],"gpt_icon":0},{"id":"2525896099","title":"Q4 Patient Monitoring Earnings Review: First Prize Goes to Masimo (NASDAQ:MASI)","url":"https://stock-news.laohu8.com/highlight/detail?id=2525896099","media":"StockStory","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2525896099?lang=en_us&edition=fundamental","pubTime":"2025-04-08 17:04","pubTimestamp":1744103068,"startTime":"0","endTime":"0","summary":"Let’s dig into the relative performance of Masimo  and its peers as we unravel the now-completed Q4 patient monitoring earnings season.Katie Szyman, Chief Executive Officer of Masimo, said “I am extremely excited about the opportunity to lead such an innovative organization as we refocus on our core healthcare business. There are numerous unmet clinical needs that we are well-positioned to address and we have strong momentum behind us. I look forward to interfacing with our customers and discussing our differentiated solutions for patient care. Our 2024 results clearly demonstrate the strong growth and earnings power of our healthcare business. We had a re","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/q4-patient-monitoring-earnings-review-090428202.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["PODD","IRTC",".IXIC","RMD","RMD.AU","NDAQ","MASI","DXCM"],"gpt_icon":0}],"pageSize":20,"totalPage":10,"pageCount":3,"totalSize":200,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/RMD.AU\",params:#limit:5,,,undefined,":[{"date":"2025-05-07","symbol":"RMD.AU","amount":0.053,"announcedDate":"2025-04-24","type":"dividend","lastAmount":null,"market":"AU","newRecordDate":"2025-05-08","defaultRemindTime":1746576000000,"name":"Resmed DRC","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-06-12","payableDate":"2025-05-08","currency":"USD","dateTimestamp":1746540000000,"payDate":"2025-06-12"},{"date":"2025-02-12","symbol":"RMD.AU","amount":0.053,"announcedDate":"2025-01-31","type":"dividend","lastAmount":null,"market":"AU","newRecordDate":"2025-02-13","name":"Resmed DRC","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-03-20","payableDate":"2025-02-13","currency":"USD","dateTimestamp":1739278800000,"payDate":"2025-03-20"},{"date":"2024-11-06","symbol":"RMD.AU","amount":0.053,"announcedDate":"2024-10-25","type":"dividend","lastAmount":null,"market":"AU","newRecordDate":"2024-11-07","name":"Resmed DRC","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2024-12-12","payableDate":"2024-11-07","currency":"USD","dateTimestamp":1730811600000,"payDate":"2024-12-12"},{"date":"2024-08-14","symbol":"RMD.AU","amount":0.053,"announcedDate":"2024-08-02","type":"dividend","lastAmount":null,"market":"AU","newRecordDate":"2024-08-15","defaultRemindTime":1723593600000,"name":"Resmed DRC","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2024-09-19","payableDate":"2024-08-15","currency":"USD","dateTimestamp":1723557600000,"payDate":"2024-09-19"},{"date":"2024-05-08","symbol":"RMD.AU","amount":0.048,"announcedDate":"2024-04-26","type":"dividend","market":"AU","newRecordDate":"2024-05-09","defaultRemindTime":1715126400000,"name":"Resmed DRC","recordDate":"2024-06-13","payableDate":"2024-05-09","currency":"USD","dateTimestamp":1715090400000,"payDate":"2024-06-13"}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"RMD.AU\",market:\"AU\",,,undefined,":[{"executeDate":"2020-08-19","recordDate":"2020-08-20","paymentDate":"2020-09-24","value":0.039,"currency":"USD"},{"executeDate":"2020-11-11","recordDate":"2020-11-12","paymentDate":"2020-12-17","value":0.039,"currency":"USD"},{"executeDate":"2021-02-10","recordDate":"2021-02-11","paymentDate":"2021-03-18","value":0.039,"currency":"USD"},{"executeDate":"2021-05-12","recordDate":"2021-05-13","paymentDate":"2021-06-17","value":0.039,"currency":"USD"},{"executeDate":"2021-08-18","recordDate":"2021-08-19","paymentDate":"2021-09-23","value":0.042,"currency":"USD"}]}}